

# Neurotech

7 September 2020

## Completion of Placement

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") is pleased to advise it has completed tranche two of its placement as announced on 3 July 2020 and approved by shareholders on 31 August 2020.

The Company completed the issue of 67,750,000 shares.

The Company anticipates the balance of the issues as detailed in the Appendix 2A released on 2 September 2020 to be completed on or around 14 September 2020.

This announcement has been authorised for release by Winton Willesee.

### Further Information

Winton Willesee  
Non-Executive Director  
winton@azc.com.au  
+61 410 667 844

### About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.